[go: up one dir, main page]

NO20062491L - Benzoksazinderivter og deres anvendelse - Google Patents

Benzoksazinderivter og deres anvendelse

Info

Publication number
NO20062491L
NO20062491L NO20062491A NO20062491A NO20062491L NO 20062491 L NO20062491 L NO 20062491L NO 20062491 A NO20062491 A NO 20062491A NO 20062491 A NO20062491 A NO 20062491A NO 20062491 L NO20062491 L NO 20062491L
Authority
NO
Norway
Prior art keywords
compounds
benzoxazine derivatives
formula
benzoxazine
derivatives
Prior art date
Application number
NO20062491A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20062491L publication Critical patent/NO20062491L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel (I):. eller farmasøytisk akseptable salter, solvater eller prodmgs derav, hvor R, R, R,,, R, R,,, X, Y og m er som definert her. Preparater som inneholder disse forbindelsene, anvendelsen av disse forbindelsene for fremstilling av medikamenter, så vel som metoder for fremstilling av forbindelser med formel (I), er også tilveiebrakt.
NO20062491A 2003-12-09 2006-05-31 Benzoksazinderivter og deres anvendelse NO20062491L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52837803P 2003-12-09 2003-12-09
PCT/EP2004/013557 WO2005058847A1 (en) 2003-12-09 2004-11-30 Benzoxazine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
NO20062491L true NO20062491L (no) 2006-09-06

Family

ID=34699863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062491A NO20062491L (no) 2003-12-09 2006-05-31 Benzoksazinderivter og deres anvendelse

Country Status (21)

Country Link
US (1) US7202241B2 (no)
EP (1) EP1694656B1 (no)
JP (1) JP4527730B2 (no)
KR (1) KR100827915B1 (no)
CN (1) CN100532369C (no)
AR (1) AR046753A1 (no)
AT (1) ATE371653T1 (no)
AU (1) AU2004299201B2 (no)
BR (1) BRPI0416873A (no)
CA (1) CA2547764A1 (no)
CO (1) CO5700768A2 (no)
DE (1) DE602004008668T2 (no)
ES (1) ES2291984T3 (no)
IL (1) IL175817A0 (no)
MY (1) MY145576A (no)
NO (1) NO20062491L (no)
NZ (1) NZ547120A (no)
RU (1) RU2354651C2 (no)
TW (1) TW200522953A (no)
WO (1) WO2005058847A1 (no)
ZA (1) ZA200604725B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322539B2 (en) 2001-07-20 2007-09-27 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
WO2006037482A2 (en) * 2004-09-30 2006-04-13 F. Hoffmann-La Roche Ag Compositions and methods for treating cognitive disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
WO2011023753A1 (en) * 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
CN101836993B (zh) 2010-05-20 2011-06-22 山东大学 2，3-二氢-3-羟甲基-6-氨基-[1，4]-苯并噁嗪在制备诱导胚胎干细胞向血管内皮细胞分化药物中的应用
CN102060810B (zh) * 2010-12-20 2012-07-04 金坛市爱特生物科技有限公司 一种n-叔丁氧羰基-哌嗪的提纯方法
CA2939305A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族ヘテロ環誘導体及びその医薬的適用
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en) 2015-06-11 2022-04-20 The Regents of the University of Michigan Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CN109568321B (zh) * 2019-01-14 2022-02-22 山东轩竹医药科技有限公司 RORγ调节剂
TW202220958A (zh) * 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8803419D0 (en) * 1988-02-15 1988-03-16 Erba Carlo Spa 1 4-benzoxazine & 1 4-benzothiazine derivatives & process for their preparation
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
AU732863B2 (en) 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
EE200100540A (et) * 1999-04-28 2002-12-16 Dr. Reddy's Research Foundation Asendusega bitsüklilised heterotsüklid, nende valmistamismeetod ja kasutamine rasvumisvastaste ja hüpokolesteroleemsete agensitena
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US20020013314A1 (en) 2000-02-01 2002-01-31 Bing-Yan Zhu 3,4-dihydro-2H-benzo[1,4]oxazine inhibitors of factor Xa
CA2485136C (en) * 2002-05-13 2011-12-20 F. Hoffmann-La Roche Ag Benzoxazine derivatives as 5-ht6 modulators and uses thereof
JP4401297B2 (ja) * 2002-11-08 2010-01-20 エフ．ホフマン−ラ ロシュ アーゲー 置換ベンゾオキサジノン及びその使用

Also Published As

Publication number Publication date
KR100827915B1 (ko) 2008-05-07
ZA200604725B (en) 2007-12-27
AU2004299201B2 (en) 2009-12-03
RU2006124513A (ru) 2008-01-27
IL175817A0 (en) 2006-10-05
TW200522953A (en) 2005-07-16
EP1694656B1 (en) 2007-08-29
EP1694656A1 (en) 2006-08-30
AR046753A1 (es) 2005-12-21
MY145576A (en) 2012-02-29
CN1890227A (zh) 2007-01-03
KR20060097758A (ko) 2006-09-15
CN100532369C (zh) 2009-08-26
CA2547764A1 (en) 2005-06-30
AU2004299201A1 (en) 2005-06-30
NZ547120A (en) 2009-02-28
RU2354651C2 (ru) 2009-05-10
ATE371653T1 (de) 2007-09-15
BRPI0416873A (pt) 2007-02-27
ES2291984T3 (es) 2008-03-01
JP4527730B2 (ja) 2010-08-18
US7202241B2 (en) 2007-04-10
JP2007513904A (ja) 2007-05-31
US20050124613A1 (en) 2005-06-09
WO2005058847A1 (en) 2005-06-30
CO5700768A2 (es) 2006-11-30
DE602004008668T2 (de) 2008-06-12
DE602004008668D1 (de) 2007-10-11

Similar Documents

Publication Publication Date Title
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20066055L (no) Pyridinderivater
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20062491L (no) Benzoksazinderivter og deres anvendelse
NO20050828L (no) lndol-3-svovelderivater
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20081844L (no) Terapeutiske forbindelser
NO20065904L (no) Terapeutiske forbindelser
NO20055977L (no) Nye benzimidazolderivater
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20040881L (no) Orale antidiabetes midler.
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20065060L (no) Farmasoytiske kombinasjoner inneholdende benzoksazin for behandling av respiratoriske forstyrrelser
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20054787D0 (no) Indenderivater som farmasotiske midler
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application